88 articles - From Friday Sep 11 2026 to Friday Sep 18 2026
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Am J Gastroenterol |
|---|
| HE guidelines in practice. |
| ISOLATED LARYNGOPHARYNGEAL SYMPTOMS DO NOT PREDICT OBJECTIVE REFLUX EVIDENCE: AN INTERNATIONAL MULTICENTER VALIDATION STUDY OF THE SAN DIEGO CONSENSUS PATHWAY FOR SELECTIVE UPFRONT TESTING.
Clinical presentation of isolated LPS is not predictive of LPRD, unlike LPS with typical symptoms. Our findings support the San Diego Consensus recommendations for selective up-front testing in isolated LPS. |
| Clin Gastroenterol Hepatol |
| AGA Clinical Practice Update on Management of Ampullary Neoplasms: Expert Review.
If high-risk features are present, long-term endoscopic monitoring is required. BEST PRACTICE ADVICE 15: Patients with high-grade dysplasia, incomplete resection, or suspected malignancy should be discussed by a multidisciplinary team that includes gastroenterologists, surgeons, and oncologists. |
meta-analyses and systematic reviews
| Gut |
|---|
| Patient-level predictors of safety and recurrence after cold versus hot snare resection of large, non-pedunculated colorectal polyps: an individual patient data meta-analysis of four randomised-controlled trials.
Cold resection is safer than hot EMR but results in more than double the RRA in al adenoma subgroups, especially those with high-grade dysplasia. It may be appropriate for SSLs between 2 cm and 4 cm and selected cases under anticoagulant/antiplatelet therapy or multimorbid patients, for which further studies are needed. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta.
The LGP2 Q425R variant is independently associated with a reduced risk of cirrhosis in European untreated patients with CHD. These results confirm in vivo that enhanced host innate immune responses modulate the natural history of CHD in vivo. |
| Clinical Trial: Randomised Placebo-Controlled Trial of Methylcellulose and Psyllium Gels on Inulin-Induced Colonic Gas.
Methylcellulose and psyllium reduce colonic gas produced by inulin after the gels reach the colon. Methylcellulose increases the water content of both the small and large bowel more than psyllium. This additional effect may allow improved tolerance of FODMAPs, particularly in IBS patients with constipation. |
| HLA-A*11:01 Identifies Patients at Risk for Persistent Viraemia and Advanced Fibrosis in HDV Infection.
HLA-A*11 01 identifies a subgroup of HDV patients at high risk of persistent viral replication and advanced fibrosis. The integration of HLA genotyping into risk stratification algorithms may help to early identify patients requiring intensified monitoring and timely therapeutic intervention. |
| Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).
Upadacitinib was effective and well-tolerated in AT-experienced CD, including patients with active EIMs, with induction benefit maintained through 6 months without novel safety signals. |
| Am J Gastroenterol |
| COMPARATIVE REAL-WORLD EFFECTIVENESS OF BIOLOGIC THERAPIES FOR PREVENTING POSTOPERATIVE ENDOSCOPIC RECURRENCE OF CROHN'S DISEASE.
In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure. |
| Comparison of demographic, clinical, and psychological characteristics among patients with irritable bowel syndrome meeting the Rome clinical, Rome V, and Rome IV criteria.
The Rome clinical criteria identify a clinically meaningful IBS population, with approximately one in five individuals missed by the Rome V criteria. These patients have a disease burden comparable to those meeting the Rome V criteria only. |
| Life expectancy and changing causes of mortality in familial adenomatous polyposis (FAP).
Recent FAP cohorts now have mortality comparable to the general population. Although colorectal mortality has declined, gastroduodenal and non-FAP-related causes have increased, underscoring the need for continued surveillance and broader long-term management strategies. |
| Long-term Outcomes After Endoscopic Resection for pMM/SM1 Esophageal Cancer: A Multicenter Prospective Cohort Study.
Post-ER pMM/SM1 esophageal cancer is associated with excellent long-term survival. Surveillance is a reasonable option for many LVI-negative cases, although additional treatment may be considered for selected higher-risk patients. |
| Noninvasive Prediction of Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: A Tumor-Adjusted Model.
Tumor burden and location affect LSM-based CSPH assessment. The proposed Baveno-HCC model improves CSPH prediction and supports more accurate risk stratification and clinical decision-making in patients with HCC. |
| Clin Gastroenterol Hepatol |
| Assessing Strategies to Mitigate the Effect of Age When Using FIB-4 Index to Screen for MASLD-Related Liver Fibrosis.
In adults with MASLD, strategies to limit age effect on FIB-4 maintained discrimination relative to standard FIB-4. An age-independent approach (FIB-3) maintains diagnostic accuracy across diverse age strata, supporting further prospective evaluation in primary-care screening populations. |
| Baseline Magnetic Resonance Enterography Stratifies Persistence Risk of Crohn's Disease Strictures.
Baseline MRE integrating activity-related and structural imaging severity stratified stricture persistence and was associated with subsequent surgery. This framework should be interpreted as a baseline imaging severity and risk-stratification tool rather than an inflammatory-fibrotic phenotype classifier. |
| Endoscopist Adherence to Post-polypectomy Surveillance Interval Recommendations Following Removal of 1-4 Non-advanced Adenomas.
Since the update to post-polypectomy surveillance guidelines in 2020, endoscopist adherence to recommended follow-up intervals for patients with 1-2 NAAs has improved. However, adherence to recommended follow-up intervals remains lower for patients with 1-2 NAA compared to those with 3-4 NAAs. These disparate adherence rates suggest that the potential for over-surveillance is substantially higher for patients with 1-2 versus 3-4 NAAs. |
| Integrated metabolomic and genetic profiling implicate loss of docosahexaenoic acid in the link between ultra-processed foods and Crohn's disease.
Our findings suggest lower circulating DHA may represent one metabolic pathway linking UPF intake to increased CD risk, apart from additive harm to metabolic depletion. This highlights potential targets for precision nutrition in CD prevention in future trials. |
| Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis.
One-quarter of participants with MASLD cirrhosis present before age 50 years and have distinct features, including higher genetic risk and a greater prevalence of T2DM. |
| Endosc Int Open |
| Utility of Underwater Peroral Endoscopic Myotomy with Near-Focus Magnification for Severe Submucosal Fibrosis.
uPOEM is safe and appeared feasible in severe SMF, yielding favorable short-term outcomes. Near-focus magnification allows better identification of the submucosal layer allowing for more precise dissection. |
| Endoscopy |
| Diagnostic performance of the Japan Narrow-Band Imaging Expert Team and pit pattern classifications for small polyps using next-generation endoscopy.
JNET showed similar observed diagnostic performance across expertise levels, whereas pit pattern classification showed greater between-group differences in sensitivity and negative predictive value. These findings suggest that JNET may serve as a practical framework for routine optical diagnosis of small lesions. |
| Endoscopic ultrasound-guided gallbladder drainage with or without prior percutaneous transhepatic gallbladder drainage: a multicenter retrospective cohort study.
Both approaches achieved high procedural success within their respective distinct pathways. Prior PTGBD did not appear to compromise subsequent EUS-GBD, suggesting that cEUS-GBD may serve as a valid internalization option in selected patients after initial PTGBD. The shorter procedure time with pEUS-GBD should be interpreted as a workflow-related finding, and the index gallbladder drainage modality should be individualized according to clinical stability, anatomic feasibility, and available endoscopic resources. |
| Risk Stratification Model for Surveillance Interval Extension After Hot Endoscopic Mucosal Resection of Large Non-Pedunculated Colon Polyps.
A simple four-factor model incorporating prior resection, margin ablation, villous histology, and ICV involvement stratifies recurrence detection risk after hot EMR. Absence of high-risk features may help identify patients at lower recurrence risk and provides a framework for future prospective studies evaluating risk-adapted surveillance strategies. |
| Gut |
| Divergent microbial preludes to necrotising enterocolitis defined by gut phages and bacterial resistomes.
The gut prophageome serves as both a source of pre-symptomatic predictive signals and an active modulator of NEC pathogenesis, with distinct microbial mechanisms driving early-onset and late-onset disease. These polymicrobial etiologies inform strategies for early detection, risk stratification and the development of microbiome-targeted preventive and therapeutic interventions. |
| HBV induces immunosuppressive macrophages via metabolic and epigenetic reprogramming to facilitate the establishment of chronic persistent infection.
HBV controls monocyte-to-macrophage fate via HBsAg-mediated metabolic-epigenetic-immune cascades to facilitate chronic persistent infection. These metabolic-epigenetic axes represent potential therapeutic targets. |
| Heterozygous germline mutations in <i>MSH3</i>, and probably <i>MLH3</i>, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk.
Background deficiency. |
| Impact of non-enteric-coated pancreatic enzyme replacement therapy (NEPERT) on pain in patients with chronic pancreatitis: a double-blind, parallel-group, placebo-controlled, randomised trial.
In adults with painful CP, NEPERT did not improve pain compared with placebo. |
| Longitudinal gut microbiome dynamics during immunotherapy identify microbial features of clinical benefit in advanced primary liver cancer.
The gut microbiome undergoes structured ecological remodelling during ICI therapy; on-treatment longitudinal windows improve pretreatment signature portability and support microbiome-guided stratification in immuno-oncology. |
| NCACC maps cross-sample spatial niches and reveals cIgG<sup>+</sup> epithelial rare cells driving liver cancer invasion.
Our study establishes NCACC as a generalisable framework for high-confidence rare malignant cell identification across heterogeneous spatial transcriptomic cohorts, highlighting the cIgG-JAK-STAT as a therapeutically actionable driver of liver cancer invasion. |
| Hepatology |
| Lactulose with or without TeleTai-Chi for the prevention of falls: A sequential multiple assignment randomized controlled trial (LiveSMART).
In patients with cirrhosis and portal hypertension without prior overt HE, lactulose reduced falls and fall-related harms. Sequential lactulose followed by TeleTai-Chi was also superior to enhanced usual care. |
| VPS13D protects against alcohol- associated steatohepatitis by regulating organelle contacts and VLDL secretion.
Loss of hepatic VPS13D disrupts mitochondria-ER contact sites, decreasing hepatic PC content and VLDL secretion, promoting ethanol-induced steatosis, progenitor cell accumulation, and liver injury. ER-mitochondrial contact disruption and altered phospholipid homeostasis may be pathogenic drivers in AH. |
| J Hepatol |
| Mouse models of acute and chronic hepatitis E virus infection.
We developed two mouse models using AG129 and C57BL/6J mice, both of which support efficient HEV-C1 replication. This work establishes the first immunocompetent mouse model for HEV infection. These mouse models offer a robust platform for studying HEV immunopathogenesis, evaluating antivirals and vaccines, and investigating mechanisms of cross-species transmission. Genbank accession numbers PX496820, PX572923 RNA-Seq data IMPACT AND IMPLICATIONS HEV research is hampered by the lack of suitable small-animal models, and our study fills this gap by establishing two mouse models, particularly the immunocompetent C57BL/6J mouse model, which should support the use of versatile genetic and immunological tools for deep mechanistic studies in the future. This study also provides a single-cell atlas of HEV infection dynamics, revealing intrahepatic viral tropism. We identified CD4 + T cell depletion as a pivotal driver of chronic infection. These mouse models offer a robust platform for studying HEV immunopathogenesis, evaluating antivirals and vaccines, and investigating mechanisms of cross-species transmission. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Amino Acid Imbalance and Prognosis in Cirrhosis. |
| Editorial: Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis. |
| Editorial: MetALD-ALD Prediction Index-A Scalable Biomarker for Alcohol Phenotyping Beyond PEth. |
| Editorial: Refractory Eosinophilic Oesophagitis-True Resistance or Suboptimal Management? |
| Editorial: Treatment Sequencing in Inflammatory Bowel Disease: Does the Line Matter More Than the Mechanism? |
| Gastrointest Endosc |
| A note from the Editor-in-Chief. |
| Beyond the scope: the transition from visual artificial intelligence to embodied humanoid robotics in flexible gastrointestinal endoscopy. |
| Blown-out myotomy after peroral endoscopic myotomy: revisiting the chicken-and-egg dilemma. |
| Circumferential esophageal endoscopic submucosal dissection: beyond technical success to long-term management. |
| Cirrhosis and achalasia: How bold can we be? |
| Endoscopic ultrasound-guided radiofrequency ablation for high-risk pancreatic cysts: navigating the middle ground between observation and operation. |
| Linked-color imaging with computer-aided detection: potential decrease in missed adenomas of right-sided colon adenomas. |
| Post-endoscopic retrograde cholangiopancreatography bleeding: How well do we know the risk factors? |
| Salvage endoscopic submucosal dissection for local gastric recurrence following endoscopic resection: Is organ preservation a reality or a risk? |
| Gut |
| Ferroptosis, immune activation and MASH-related HCC.
We establish a novel cell-type-specific transcriptomic framework governed by a core four-gene signature ( By evaluating the sexual dimorphism embedded within these pathways, specifically how the DTL-PROX1 axis dictates distinct iron accumulation rates and lipid peroxidation sensitivities, we propose precise clinical stratification strategies. Finally, we outline actionable translational avenues, highlighting how targeting the ferroptosis-immune axis offers a highly specific therapeutic window to arrest lipotoxicity, suppress inflammation and disrupt oncogenic priming before irreversible tissue remodelling occurs. |
| International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.
We offer practical recommendations for individualising therapy by patient phenotype, managing patients already receiving GLP-1 RAs and defining response, non-response and criteria for switching or combining agents. The proposed framework is intended to evolve as long-term outcomes data emerge and additional MASH therapies become available. |
| Orchestrated cell death pathways in cholangiopathies.
However, they do not directly target the molecular networks governing cholangiocyte death, which may partly explain their limited impact on fibrosis and long-term outcomes. In this review, we synthesise current knowledge on regulated cell death mechanisms in cholangiopathies, highlight key conceptual and technical challenges that complicate their interpretation and therapeutic targeting, and discuss how sublethal death signalling may connect with senescence to sustain cholangiopathy progression and shape therapeutic perspectives. |
| J Hepatol |
| Liver transplantation for primary liver cancers in the era of transplant oncology.
Following transplantation, minimisation of immunosuppression is essential to balance graft preservation against tumour immune surveillance, although the persistence of antitumour immunity after pre-transplant immunotherapy remains uncertain. Emerging biomarkers, including circulating tumour DNA, circulating tumour cells, and microRNAs, have the potential to improve candidate selection, detect minimal residual disease, and enable earlier, biology-driven identification of recurrence, thereby supporting a more personalised approach to LT in primary liver cancers. |
| The use of locoregional therapies in cholangiocarcinoma.
Until further evidence from randomised controlled trials becomes available, treatment strategies for patients with unresectable or advanced CCA should be individualised, incorporating flexible, staged combinations of locoregional and systemic therapies within a personalised therapeutic framework. These decisions should be made within a multidisciplinary tumour board. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Baseline characteristics of a prospective, multi-center study on the natural history of compensated cirrhosis: the Liver Cirrhosis Network. |
| Reconsidering Surveillance in Non-dysplastic Barrett's Esophagus: When Doing Less Is the Right Choice. |
| Endoscopy |
| An endobronchial ultrasound scope enables endoscopic ultrasound-guided tissue acquisition for pancreatic lesions in a patient with trismus. |
| Appendicoscopy for the observation of acute appendiceal hemorrhage. |
| Artificial intelligence-assisted endoscopic ultrasonography for the detection of a small T1 pancreatic ductal adenocarcinoma in a difficult-to-puncture location. |
| Contrast-enhanced endoscopic ultrasound for vascular mapping: a paradigm shift from target enhancement to danger marking in endoscopic ultrasound-guided biliary drainage. |
| Dual-tunnel endoscopic submucosal dissection for circumferential early gastric cancer involving the pylorus and duodenal bulb. |
| Endoscopic salvage of a complex post-endoscopic mucosal resection duodenal perforation. |
| Gel-immersion endoscopy revealing hemobilia masquerading as duodenal stent-related bleeding. |
| Mid-route pancreatic duct seeking during endoscopic ultrasound-guided pancreatic duct drainage. |
| Multidirectional traction-assisted rectal endoscopic submucosal dissection with prophylactic Glubran 2 nebulization in a high-risk bleeding patient receiving ongoing anticoagulant therapy. |
| See better, treat better - cap-assisted single-operator pancreatoscopy for electrohydraulic lithotripsy of pancreatic duct stones. |
| Successful endoscopic closure of a duodenal anastomotic leak using a through-the-scope suturing device. |
| When pain persists after peroral endoscopic myotomy: endoscopic management of a large postprocedural intramural esophageal hematoma. |
| Gastrointest Endosc |
| ENDOSCOPIC DECOMPRESSION OF CONGENITAL DIAPHRAGMATIC INCARCERATION. |
| Gut |
| Global epidemiology of disorders of gut-brain interaction: new insights with Rome V. |
| Hepatology |
| From meaningful change to reliable response assessment: Editorial on "Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH". |
| Polyendocrine metabolic ovarian syndrome (PMOS): The impact of terminology update through the lens of gastroenterology & hepatology. |
| J Hepatol |
| Modulation instead of depletion: Rethinking B cell-targeted therapies in IgG4-related cholangitis. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Letter: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus-Are We Really Sure It Is Dysplasia? |
| Letter: Circulating DNA After Liver Transplantation: Distinguishing Tumour Recurrence From Allograft Injury. |
| Letter: Cohort Provenance and Independence in Treatment-Relevant Enhanced Liver Fibrosis Thresholds. |
| Letter: From qHBsAg Correlation to Clinical Stratification-What Evidence Is Still Needed for Rapid HBsAg Time to Positivity? Authors' Reply. |
| Letter: Proton Pump Inhibitors in Autoimmune Gastritis. |
| Letter: When Does the Risk Clock Start in Immune Checkpoint Inhibitor-Associated Coeliac Disease? |
| Clin Gastroenterol Hepatol |
| Letter to the Editor re: A Randomized Trial of Rifaximin vs Low FODMAP Diet. |
| NEGATIVE CLINICAL TRIALS CAN YIELD POSITIVE INSIGHTS. |
| Endosc Int Open |
| Regarding Clinical Management of Polyposis: Do You Mind? |
| Gastrointest Endosc |
| A practical "grasp-and-release" technique for nasojejunal tube placement in small infants. |
| Are endoscopic ultrasound-guided choledochoduodenostomy and gallbladder drainage interchangeable for malignant distal biliary obstruction? |
| Competing mortality, not age or sex, may explain the loss of benefit from colonoscopy in adults aged 80 to 85 years. |
| Defining underwater endoscopic submucosal dissection in network meta-analysis: implications of dual-approach endoscopic submucosal dissection. |
| Endoscopic band ligation remains a cost-effective first-line option despite higher recurrent bleeding rates compared with over-the-scope clip for colonic diverticular bleeding. |
| Interpreting histologic end points after endoscopic gastric remodeling for metabolic dysfunction-associated steatohepatitis. |
| Interpreting long-term outcomes of endoscopic ultrasound-guided radiofrequency ablation for branch-duct intraductal papillary mucinous neoplasm in nonsurgical patients. |
| Is endoscopic submucosal dissection a suitable rescue technique for all recurrent scarred flat polyps or only for some? |
| Steroid lifting method during esophageal endoscopic submucosal dissection: clarification regarding prior description of submucosal steroid injection. |
| J Hepatol |
| Curative conversion and confounding in a bevacizumab dose comparison. |